Who founded Synvivia?

Synvivia was founded by Gabriel Lopez.

Who are Synvivia's investors?

Synvivia's investors include CAL Innovation, California Innovation Fund, Creative Ventures, Gaingels, Metaplanet, Thundermark Capital, Y Combinator, For Good Ventures and 3 more.

How much funding has Synvivia raised?

Synvivia has disclosed $54.1K raised across 1 round.

Where is Synvivia headquartered?

Synvivia is headquartered in San Francisco, US.

Synvivia

YC S16

San Francisco, US · Delaware corporation · 4 employees · 11 known investors

Find your way into Synvivia

Paths you didn't know you had: your email and LinkedIn already hold routes to the Synvivia team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Synvivia engineers molecules designed to reprogram cells. The company operates in the biotech sector.

AI & Machine Learning Biotech Healthtech Artificial Intelligence Synthetic Biology Manufacturing Drug discoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (S16)

Gabriel Lopez CEO, FounderGabriel Lopez is founder and CEO of Synvivia, a biotech company that develops technology for biopharmaceutical manufacturing optimization.

Investors · 11

CAL Innovationlisted by CAL InnovationMill Valley

California Innovation Fundlisted by California Innovation FundBerkeley

How we know: California Innovation Fund's portfolio page · Not right? Tell us

Creative Ventureslisted by Creative VenturesSan Francisco Bay Area · $1M

How we know: Creative Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Gaingelslisted by GaingelsNew York · $200K – $500K

How we know: gaingels.com · Not right? Tell us

Metaplanetlisted by MetaplanetTallinn · $500K – $10M

How we know: Metaplanet's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Thundermark Capitallisted by Thundermark CapitalSan Juan

How we know: Thundermark Capital's portfolio page · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

For Good Venturesreported

How we know: Y Combinator's founder network · open dataset · 5k.vc investor directory · Not right? Tell us

Lightspeed Venture PartnersreportedMenlo Park · $1M – $5M

How we know: Y Combinator's founder network · Not right? Tell us

Sam Altmanreported

How we know: Y Combinator's founder network · Not right? Tell us

Tencent HoldingsreportedShenzhen

How we know: Y Combinator's founder network · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$54.1K disclosed across 1 round · 2023

▶$54.1KraisedDec 2023 · 1 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Gabriel LopezExecutive Officer, Director

Offering amount: $54.1K
Amount sold: $54.1K
First sale: Dec 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

ACXACX develops bioengineered solutions for pest control in agriculture, replacing synthetic chemicals with precision biocides. The company serves crop producers and aims to enhance food security while reducing chemical dependence and promoting biodiversity.

ParcelBioParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

Abalone BioAbalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning. The company uses large-scale biological measurement platforms and AI-powered sequence analysis to discover functional antibody drugs for pharmaceutical and biotechnology applications.

Sensible BiotechnologiesSensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.

Companies working in the same space as Synvivia.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Science Foundation	Phase I	2022	$255.9K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2016	$295.2K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure

Synvivia, Inc.

Frequently asked questions

What does Synvivia do?: Synvivia engineers molecules designed to reprogram cells. The company operates in the biotech sector.
Who founded Synvivia?: Synvivia was founded by Gabriel Lopez.
Who are Synvivia's investors?: Synvivia's investors include CAL Innovation, California Innovation Fund, Creative Ventures, Gaingels, Metaplanet, Thundermark Capital, Y Combinator, For Good Ventures and 3 more.
How much funding has Synvivia raised?: Synvivia has disclosed $54.1K raised across 1 round.
Where is Synvivia headquartered?: Synvivia is headquartered in San Francisco, US.